Skip to main content
Home > The Daily Extra > Top Story

Chronological Index of : Top Story

 Current Issue
  • TOP STORY: Circassia raises L200M in London IPO

    Allergy company Circassia Pharmaceuticals plc (LSE:CIR) raised L200 million ($334.2 million) through the sale of 64.5 million shares at 310p in an IPO on the London Stock Exchange -- the largest biotech IPO in the U.K.,…

    Published on 3/13/2014
  • TOP STORY: Achaogen raises $72 million in IPO

    Infectious disease company Achaogen Inc. (NASDAQ:AKAO) jumped $2.30 (19%) to $14.30 on its first day of trading Wednesday after raising $72 million in an IPO through the sale of a bumped-up number of shares at the low …

    Published on 3/12/2014
  • TOP STORY: Sanofi, UCB in deal for immune-mediated diseases

    Sanofi (Euronext:SAN; NYSE:SNY) and UCB Group (Euronext:UCB) partnered to jointly discover and develop oral small molecules targeting undisclosed pathways to treat immune-mediated diseases. The partners will use an …

    Published on 3/11/2014
  • TOP STORY: Alexion ups guidance

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) raised its 2014 guidance after reaching an agreement with the French government over reimbursement for Orphan drug Soliris eculizumab. The company is not disclosing details of …

    Published on 3/10/2014
  • TOP STORY: Companies with PCSK9 inhibitors fall on FDA concerns

    Several companies developing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors fell on Friday on Twitter reaction to FDA concerns about neurocognitive adverse events for the class. The agency's concerns …

    Published on 3/7/2014
  • TOP STORY: Synageva raises $211 million in follow-on

    Synageva BioPharma Corp. (NASDAQ:GEVA) raised $211 million on Thursday through the sale of 2 million shares at $105.75 in the largest follow-on so far this year. The company proposed the offering late Tuesday, when its …

    Published on 3/6/2014
  • TOP STORY: Eisai, Biogen Idec partner for AD compounds

    Eisai Co. Ltd. (Tokyo:4523) and Biogen Idec Inc. (NASDAQ:BIIB) partnered to co-develop and co-commercialize Eisai's E2609 and BAN2401 for Alzheimer's disease. Eisai will receive an undisclosed upfront payment and is …

    Published on 3/5/2014
  • TOP STORY: Synageva proposes follow-on

    Synageva BioPharma Corp. (NASDAQ:GEVA) proposed late Tuesday to sell 2 million shares in a follow-on underwritten by Goldman Sachs; JPMorgan; and Morgan Stanley. If sold at Synageva's close of $103.99 on Tuesday, before…

    Published on 3/4/2014
  • TOP STORY: NICE wants details on Soliris' development cost

    The U.K.'s NICE requested information on the development costs for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to treat atypical hemolytic uremic syndrome (aHUS), as well as an explanation of how …

    Published on 3/3/2014
  • TOP STORY: Abide grants Celgene options

    Celgene Corp. (NASDAQ:CELG) paid Abide Therapeutics Inc. (Princeton, N.J.) $50 million up front in exchange for an exclusive option to acquire Abide for undisclosed terms. Celgene gained an undisclosed equity stake in …

    Published on 2/28/2014
  • TOP STORY: Camp proposes to repeal Orphan credit

    Rep. David Camp (R-Mich.) released a discussion draft of sweeping draft tax reform legislation that includes a proposal to repeal the 50% tax credit for clinical development costs of Orphan drugs. Camp is chairman of …

    Published on 2/27/2014
  • TOP STORY: Subcommittee against Part D drug class changes

    At a Wednesday hearing of the health subcommittee of the U.S. House of Representatives Energy and Commerce Committee, members voiced concerns about the elimination of two protected drug classes under CMS's proposed …

    Published on 2/26/2014
  • TOP STORY: InterMune leaps on Esbriet data

    InterMune Inc. (NASDAQ:ITMN) jumped $23.84 (171%) to $37.80 on Tuesday after reporting that daily Esbriet pirfenidone met the primary endpoint in the 555-patient Phase III ASCEND trial to treat idiopathic pulmonary …

    Published on 2/25/2014
  • TOP STORY: ThromboGenics exploring strategic options

    ThromboGenics N.V. (Euronext:THR) jumped EUR 3.64 (19%) to EUR 22.40 on Monday after announcing it hired Morgan Stanley and plans to explore strategic options. ThromboGenics declined to provide details. The company …

    Published on 2/24/2014
  • TOP STORY: Isis jumps on interim SMA data

    RNAi play Isis Pharmaceuticals Inc. (NASDAQ:ISIS) added $920.5 million in market cap on Friday after reporting top-line data from a Phase Ib/IIa trial evaluating the company's ISIS-SMNRx to treat spinal muscular atrophy…

    Published on 2/21/2014
  • TOP STORY: CHMP backs two COPD products

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Theravance Inc. (NASDAQ:THRX) said EMA's CHMP recommended approval of an MAA from GSK for Anoro Ellipta umeclidinium bromide/vilanterol as a once-daily maintenance …

    Published on 2/20/2014
  • TOP STORY: Lilly's ramucirumab meets in NSCLC trial

    Eli Lilly and Co. (NYSE:LLY) said IV ramucirumab (LY3009806) plus docetaxel met the primary endpoint of improving overall survival (OS) vs. placebo plus docetaxel in the Phase III REVEL trial to treat advanced non-small…

    Published on 2/19/2014
  • TOP STORY: Actavis to acquire Forest

    Generics company Actavis plc (NYSE:ACT) will acquire specialty pharma Forest Laboratories Inc. (NYSE:FRX) in a cash and stock deal that the companies said values Forest at about $89.48 per Forest share, or about $25 …

    Published on 2/18/2014
  • TOP STORY: FDA approves BioMarin's Vimizim

    FDA approved a BLA from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome). The company said it immediately launched the recombinant …

    Published on 2/14/2014
  • TOP STORY: PTC raises $110 million in follow-on

    PTC Therapeutics Inc. (NASDAQ:PTCT) raised $110 million through the sale of 4.5 million shares at $24.50 in a follow-on underwritten by JPMorgan and Credit Suisse. PTC filed to raise up to $75 million in the offering in…

    Published on 2/13/2014
  • TOP STORY: FDA approves Imbruvica for CLL

    FDA granted accelerated approval to Imbruvica ibrutinib from Pharmacyclics Inc. (NASDAQ:PCYC) and partner Johnson & Johnson (NYSE:JNJ) to treat chronic lymphocytic leukemia (CLL) in patients who have received at least …

    Published on 2/12/2014
  • TOP STORY: Mallinckrodt to acquire Cadence

    Specialty pharma Mallinckrodt plc (NYSE:MNK) gained $6.88 (12%) to $66.19 on Tuesday after announcing it will acquire Cadence Pharmaceuticals Inc. (NASDAQ:CADX) for $14 per share in cash, or about $1.3 billion on a …

    Published on 2/11/2014
  • TOP STORY: FDA reviewers mixed on MDCO's cangrelor

    Briefing documents on cangrelor show a rift between FDA staffers on one of the two indications proposed by The Medicines Co. (NASDAQ:MDCO). The clinical and safety reviewers jointly recommended approval of cangrelor to …

    Published on 2/10/2014
  • TOP STORY: Roche fights back on Herceptin biosimilar

    Roche (SIX:ROG; OCTQX:RHHBY) filed suit in India against the Drugs Controller General of India (DCGI), Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) and Mylan Inc. (NASDAQ:MYL) "seeking to clarify" that the partners "have …

    Published on 2/7/2014
  • TOP STORY: Hamburg: FDA regulation not 'one size fits all'

    FDA Commissioner Margaret Hamburg defended the agency's flexibility during the drug development and approval process and said she "would be more troubled if FDA used a rigid, 'one size fits all' approach." Hamburg's …

    Published on 2/6/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993